腺病毒载体双价疫苗针对野生型SARS-CoV-2和奥密克戎变异株在小鼠模型中的免疫原性
本研究在小鼠模型中评估了靶向野生型SARS-CoV-2和奥密克戎变异株的腺病毒载体双价疫苗(Ad5-nCoV/O)的免疫原性。单剂初免及异源或同源加强免疫后,双价疫苗均诱导了针对野生型和奥密克戎变异株的广谱交叉中和抗体和细胞免疫应答,鼻内加强还诱导了黏膜IgA应答。
要点
- 单剂双价Ad5-nCoV/O初免可诱导针对野生型和奥密克戎株的抗体及CD4+、CD8+细胞应答。
- 以灭活疫苗或Ad5载体疫苗初免后,双价疫苗肌肉或鼻内加强均诱导强血清中和抗体应答。
- 灭活疫苗初免后以Ad5载体疫苗加强时,异源初免-加强的中和抗体应答优于同源初免-加强。
核心结论
- 双价疫苗Ad5-nCoV/O表现出强免疫原性,诱导针对野生型和奥密克戎变异株的广谱交叉中和抗体和细胞免疫应答。
- 结果证明该双价疫苗在应对新出现的SARS-CoV-2奥密克戎变异株挑战方面具有潜力。
研究设计与样本
- 小鼠模型研究:单次免疫模型中,小鼠经肌肉注射单剂针对野生型SARS-CoV-2和奥密克戎变异株的单价或双价Ad5载体疫苗。
- 初免-加强模型中,小鼠先经肌肉注射针对野生型SARS-CoV-2的灭活疫苗或Ad5载体疫苗初免,再经肌肉或鼻内途径以异源或同源的灭活疫苗、单价或双价Ad5载体疫苗加强。
- 采用ELISA、假病毒中和试验、胞内细胞因子染色(ICS)和ELISpot检测疫苗诱导的抗体应答和细胞免疫应答。
主要发现
- 单剂单价和双价疫苗初免均诱导了针对野生型和奥密克戎SARS-CoV-2刺突蛋白的强抗体应答及CD4+和CD8+细胞应答。
- 以灭活疫苗或Ad5载体疫苗初免后,双价Ad5-nCoV/O肌肉或鼻内加强均诱导了针对野生型和奥密克戎变异株的强血清中和抗体应答。
- 灭活疫苗初免后以Ad5载体疫苗加强时,异源初免-加强比同源初免-加强诱导了更强的中和抗体应答。
- 鼻内加强还诱导了显著的黏膜IgA应答。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The emergence and rapid spread of new mutant strains of SARS-CoV-2 necessitate the development of a new generation vaccine capable of neutralizing a broad range of variants. When the SARS-CoV-2 Omicron variant emerged, individuals in China had already received an inactivated (INA) or a type 5 adenovirus-vectored (Ad5) SARS-CoV-2 vaccine targeting the wild-type virus. We have recently developed a bivalent recombinant type 5 vaccine targeting both the wild-type strain and the Omicron variant (Ad5-nCoV/O). The objectives of this study were to assess the immunogenicity of the bivalent vaccine as a booster against both the wild type and the Omicron variant. METHODS: In the single immunization model, mice received one intramuscular immunization with monovalent or bivalent Ad5-vectored vaccines targeting both wild-type SARS-CoV-2 and Omicron variants. In the prime-boost model, mice were primed intramuscularly with an INA or Ad5-vectored vaccine targeting wild-type SARS-CoV-2, and then boosted intramuscularly or intranasally with heterologous or homologous INA or monovalent or bivalent Ad5-vectored vaccines targeting both wild-type SARS-CoV-2 and Omicron variants. The vaccine-induced antibody responses and cellular immune responses were measured using ELISA, pseudovirus-based neutralization assays, the intracellular cytokine staining (ICS) and ELISpot. RESULTS: Single-dose prime vaccination with the monovalent and bivalent vaccines elicited robust antibody responses and CD4 + and CD8 + cellular responses against the spike protein of WT and Omicron SARS-CoV-2. Both intramuscular and intranasal boost vaccination with the bivalent Ad5-nCoV/O following a prime with INA or Ad5-vectored vaccines induced strong serum neutralization antibody responses to both wild type and Omicron variants. A heterologous prime-boost vaccination elicited greater neutralization antibody responses than a homologous prime-boost vaccination when mice were boosted with Ad5-vectored vaccines following a prime with INA. Intranasal boost also resulted in significant mucosal IgA responses. CONCLUSION: The bivalent vaccine Ad5-nCoV/O exhibited robust immunogenicity, inducing broad-spectrum cross-neutralizing antibodies and cellular immune responses against both wild type and Omicron variants of SARS-CoV-2. The results demonstrated the potential of the bivalent vaccine in addressing the challenges posed by emerging SARS-CoV-2 Omicron variants.
引用
- Ji Y, Sui X, Miao W, et al. Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model. Vaccine. 2024. PMID: 38296705. doi:10.1016/j.vaccine.2024.01.073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。